I received my undergraduate degree in biological sciences from Rutgers University and my MD from UMDNJ-Robert Wood Johnson Medical School. I also have a MHSc degree from Duke University School of Medicine. After my internship and residency in Internal Medicine at North Shore University Hospital-NYU School of Medicine and Memorial Sloan-Kettering Cancer Center, I completed an oncology fellowship and a senior clinical research fellowship at the National Cancer Institute as well as a training program in Clinical Research at the National Institutes of Health. I have been at The Cancer Institute of New Jersey since 2003 and am currently an Associate Professor of Medicine at UMDNJ-Robert Wood Johnson Medical School.
I have a long-standing interest in the development of new anti-cancer drugs, and as the Director of our Phase I and Investigational Therapeutics Program, I oversee a healthcare team whose focus is on delivering promising new cancer treatments in a safe and supportive setting. My main goal is to develop, implement and conduct clinical trials with a focus on translating science discoveries to the clinic which will then create novel clinical trial opportunities for patients. As a clinical investigator specializing in breast cancer and drug development, I work collaboratively with basic scientists and industry to develop the next generation of innovative therapies for patients with breast cancer and other solid tumors. The focus of my current clinical research is novel therapeutics for the treatment of triple-negative breast cancer, which includes the evaluation of poly (ADP-ribose) polymerase (PARP) inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
As a member of the Stacy Goldstein Breast Cancer Center, I am also part of a team that takes a comprehensive approach to the care of breast cancer patients. This includes pathologists, radiologists, surgical oncologists, radiation oncologists, nurses, social workers, nutritionists and genetic specialists, and together we help patients obtain state-of-the-art treatment for their breast cancer.
Novel targets in the treatment of breast cancer, innovative clinical trial designs, triple-negative breast cancer, anti-angiogenesis
- In 2005, I was selected to receive an American Society of Clinical Oncology (ASCO) Foundation Clinical Research Career Development Award to study “Targeting the Vascular Endothelial Growth Factor Receptor in Early Stage Breast Cancer.”
- In 2012, I am a recipient of a grant from the Foundation of UMDNJ to evaluate PARP inhibitors in the treatment of breast cancer.
- I also have been invited to serve as Chair of the ASCO Cancer Education Cancer Committee for the period of 2012 – 2013.
To schedule an appointment call 732-235-8515